The validity of the class representative concept for in vitro susceptibility testing of older cephalosporins was reevaluated. Two oral cephalosporins, cephalexin and cefaclor, were compared with the established cephalosporin class representative, cephalothin, by using reference microdilution minimal inhibitory concentrations of 528 isolates of a wide variety of gram-positive and gram-negative bacterial pathogens. For each comparison, there were only 15 (2.8%) random major and very major interpretive discrepancies. Additional comparisons confirmed the need to test second-generation (cefamandole) and third-generation (cefotaxime) cephalosporins separately. These results provide reasonable assurance that the use of cephalothin as an in vitro predictor of qualitative bacterial susceptibility to these two oral cephalosporins remains an acceptable alternative to testing each antibiotic individually.
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Since the clinical introduction of cephalexin in 1971, determination of bacterial susceptibility to this oral cephalosporin has been made on the basis of the zones of inhibition produced by disks containing 30 pig of cephalothin. This practice was encouraged by a U.S. Food and Drug Administration decision endorsing the concept of testing only one antibacterial agent from each class of closely related drugs (2, 3) . The 30-pLg cephalothin disk was recommended for testing bacterial susceptibility to all cephalosporins that were clinically available at that time, i.e., cephalothin, cephaloridine, cephaloglycin, and cephalexin (3, 6) . In more recent years, a variety of other cephalosporins with essentially the same antimicrobial spectrum have become available, e.g., cefazolin, cephapirin, cephradine, cefaclor, and cefadroxil. These also are represented in the disk test by cephalothin (4) (5) (6) .
Since Cephalothin, cephalexin, cefamandole, and cefaclor (Eli Lilly & Co, Indianapolis, Ind.) and cefotaxime (Hoechst-Rouseel Pharmaceuticals, Inc., Somerville, N.J.) were incorporated into divalent cation-supplemented Mueller-Hinton broth in serial twofold concentrations over a range of 64 to 0.06 pg/ml in 0.1-ml volumes in microdilution trays (7) . Trays were inoculated with 5 x 104 CFU/well and incubated aerobically for 18 to 24 h before interpretation. The minimal inhibition concentration (MIC) was defined as the lowest antibiotic concentration that prevented formation of macroscopically visible bacterial growth. The standard method proposed by the National Committee for Clinical Laboratory Standards, standard M7-P(7), was used throughout the study. The broth was further supplemented with 5% peptic digest of horse blood when fastidious streptococci, meningococci, or H. influenzae was tested. N. gonorrhoeae isolates were tested by an agar dilution procedure, using proteose peptone no. 3, with 1% hemoglobin and 1% Kellogg supplement.
Each isolate was tested for its ability to produce ,B-lactamase by adding one drop of nitrocefin (500 ,ug/ml in pH 7 phosphate buffer) to the growth control well (8) . Nitrocefin hydrolysis tests were also performed after the microorganism had grown in the presence of inducing concentrations of cefoxitin (0.03 to 2.0 p.g/ml) and cefsulodin (0.25 to 16 ,ug/ml). The results showed that 132 strains (25%) had a strong Plactamase reaction without induction and 256 strains (48%) after exposure to the two enzymestable cephalosporins. Table 1 summarizes the major interpretive errors by using the cephalothin MIC susceptibility results to predict susceptibility to cephalexin, cefaclor, cefamandole, and cefotaxime. These data assume the susceptible and resistant breakpoints for all cephalosporins to be <8.0 ,ug/ml and -32 ,ug/ml, respectively (7) . Clearly, the use of the cephalothin MIC or, by inference, disk results (2, 4) produces acceptable predictive statistics for the oral cephalosporins (cephalexin and cefaclor). Only 2.8% combined major and very major errors were found for each durg, with 1.7% very major errors for cephalexin. The nine strains susceptible to cephalothin and resistant to cephalexin were two H. influenzae, two P. mirabilis, one S. pneuimoniae, and four methicillin-resistant S. auireus. All of the cefaclor very major errors were with methicillin-resistant S. aurelus strains. Since the National Committee for Clinical Laboratory Standards (6, 7) and other authorative groups (3) recommend that all methicillin-resistant S. aureus strains be reported as resistant to cephalosporins, the deletion of those four errors reduces the cephalexin and cefaclor very major discrepancies to 0.95% and nil, respectively. The major errors (false resistance) for cephalexin were three E. coli strains, two E. agglomerans strains, and one P. rettgeri strain. These study results ensure that the use of cephalothin as an in vitro predictor of qualitative susceptibility of bacteria to cephalexin and cefaclor remains the alternative to testing each antibiotic. Long-term varied use of the older parenteral cephalosporins and their oral counterparts has not altered the validity of the cephalothin class disk. Conversely, the more recently released cephalosporins must be tested separately from cephalothin, yet other class representatives appear to be appropriate for second-generation cephalosporins (2, 4, 6) and possibly for some of the third-generation ,B-lactams (6) .
